This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
BRD4 / Bromodomain-containing protein 4 · IHC design guide
Design Immunohistochemistry for BRD4
Plan chromogenic BRD4 staining in paraffin sections with the IHC-validated M00123 antibody (catalog: M00123). Expect broad nuclear staining (HPA tissue IHC), and compare sections with consistent fixation and appropriate controls (standard IHC practice).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
BRD4 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Ubiquitous nuclear staining (HPA tissue IHC) | |
| Staining pattern | Nuclear staining in adipocytes and glandular cells (HPA tissue IHC) | |
| Antigen retrieval | Tris-EDTA pH 9.0 HIER, 95–98 °C, 20 min (rule: nuclear antigen) | |
| Positive control | Adipose tissue+4 more · see all | |
| Negative control | None in HPA (detected in all 45 tissues); use no-primary + isotype controls |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across sections. (standard IHC practice; not target-specific) | |
| Caveat | Broad expression limits tissue-negative controls (HPA tissue IHC) | |
| Regulation | Deacetylation reduces chromatin binding (UniProt) | |
| Isoform / epitope | 3 isoforms (A, C, B); verify epitope coverage (UniProt) |
Section 1
Recommended BRD4 IHC & IF Protocols
Compare the catalog antibody’s IHC-P protocol (datasheet) with published BRD4 staining in heart sections (PMC12203807), breast tumor microarrays (PMC6053709), and gastric carcinoma sections (PMC5458191).
| Sample | Paraffin-embedded human kidney tissue; fixative not specified (datasheet M00123) |
| Fixation | Image fixative and duration unreported (datasheet M00123); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat-induced epitope retrieval in Tris-EDTA buffer, pH 9.0, 20 min at 95–98 °C (standard rule: nuclear antigen) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% normal serum of the secondary host, 30 min, room temperature (standard) |
| Primary antibody | Rabbit monoclonal (clone DBH-2) anti-BRD4, 1:50 (datasheet M00123) |
| Primary incubation | Overnight at 4 °C (standard) |
| Detection | HRP-polymer secondary, DAB chromogen 5–10 min (standard) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | BRD4-positive staining in adipocytes of adipose tissue (HPA tissue IHC: High). HPA tissue profile: Ubiquitous nuclear expression. No signal in the no-primary control. |
💡Decision noteStart with Tris-EDTA pH 9.0 HIER at 95–98 °C for 20 min (page retrieval rule: nuclear antigen); compare citrate retrieval if needed (PMC12203807; PMC5458191).
Section 2
What Is the Expected BRD4 Staining Pattern?
BRD4 should appear predominantly in nuclei in paraffin-section IHC, consistent with its nuclear and chromosomal localization and lack of a transmembrane segment (UniProt O60885: subcellular location, topology). Expect staining across many cell populations, with high signal reported in several named tissues (HPA: ubiquitous nuclear expression; low tissue specificity). The tissue IHC profile is Supported, reflecting consistency between antibody staining and RNA expression (HPA: tissue IHC reliability).
| Nuclei stain in multiple cell populations, including adipocytes or bone-marrow hematopoietic cells. | This fits the broad nuclear pattern; both named cell populations have High tissue-IHC staining (HPA: adipocytes High; hematopoietic cells High). Compare nuclear signal with the counterstain and assess whether it lies within cells. High is an HPA category, not a required intensity for every nucleus on every slide. |
| Signal is predominantly cytoplasmic or outlines cell membranes while nuclei remain clear. | This conflicts with the expected nuclear localization (UniProt O60885: nucleus, chromosome; HPA: ubiquitous nuclear expression). Treat a dominant nonnuclear pattern as suspect and review the detection controls and antibody conditions before assigning it to BRD4; this record provides no tissue-IHC basis for a membrane pattern. |
| Strong color appears in unexpected cells or acellular areas, while expected nuclei show little signal. | Cross-reactivity or endogenous detection activity is possible (standard IHC practice). BRD4 is broadly expressed, so staining in a cell type absent from the HPA examples is not, by itself, evidence of an artefact (UniProt O60885: ubiquitously expressed; HPA: low tissue specificity). Judge compartment, controls, and distribution together. |
| Color spreads across nuclei, cytoplasm, and surrounding tissue with little contrast. | Diffuse background prevents a confident localization call. Excess antibody, incomplete blocking, or detection-system background are general IHC possibilities (standard IHC practice); the supplied UniProt and HPA records do not identify a BRD4-specific cause. Reassess the slide only after a nuclear signal can be distinguished from background. |
| A section expected to contain positive cells has no convincing nuclear stain. | An absent result in adipocytes, adrenal glandular cells, or bone-marrow hematopoietic cells warrants a technical check because HPA reports High staining there (HPA: tissue IHC). Check a known-positive section in the same run before interpreting the sample as BRD4-negative (standard IHC practice). HPA supplies no target-specific fixation-sensitivity claim. |
💡Expected BRD4 appearanceCall a result positive when cell-associated nuclear staining is discernible in expected populations, including HPA High adipocytes or hematopoietic cells (HPA: tissue IHC); dominant membrane staining or color in acellular areas is a suspect pattern, not convincing BRD4 localization (UniProt O60885: nucleus, chromosome; standard IHC practice).
| Tissue and cell context | HPA describes ubiquitous nuclear expression and low tissue specificity, with High staining in adipocytes, adrenal and appendix glandular cells, bone-marrow hematopoietic cells, bronchial respiratory epithelium, and caudate glia (HPA: tissue IHC). These are useful positive examples; the payload provides no negative tissue or low-staining reference. |
| Nuclear and chromosome localization | BRD4 associates with acetylated chromatin and preferentially localizes to mitotic chromosomes (UniProt O60885: subcellular location). HPA also reports nucleoplasmic localization and mitotic-chromosome localization by ICC-IF (HPA: subcellular). A mitotic nuclear pattern can therefore be compatible with BRD4; tissue-section intensity need not match ICC-IF images. |
| Antibody evidence | The listed antibodies HPA015055, HPA061646, CAB068177, and CAB068178 each have Supported IHC status (HPA: antibody validation). Use the IHC-validated antibody's own conditions for a run; this payload supplies no catalog-antibody dilution or retrieval setting. Supported validation does not make every unexpected staining pattern specific. |
| Isoforms and processing | UniProt lists 3 isoforms—A, C, and B—and one annotated protein chain, residues 1–1362, with no signal peptide or propeptide (UniProt O60885: isoforms, processing). The supplied evidence does not locate the catalog antibody's epitope, so it cannot establish which isoforms that antibody detects. |
| IF/ICC Q: what localization should be expected? | A: Predominantly nucleoplasmic signal, with additional mitotic-chromosome localization (HPA: subcellular ICC-IF; UniProt O60885: nucleus, chromosome). HPA lists ICC-IF images in U-251MG, U2OS, MCF-7, PC-3, and KOLF2.1J (HPA: subcellular). These observations inform localization; they are not an IF/ICC protocol for this IHC page. |
| Situation | Likely cause | Next action |
|---|---|---|
| No nuclear signal in a positive-reference section. | A failed IHC run or unsuitable assay conditions are possibilities (standard IHC practice); adipocytes and bone-marrow hematopoietic cells are High examples (HPA: tissue IHC). | Check the positive control, reagent delivery, retrieval, and detection steps together (standard IHC practice). The supplied sources do not establish BRD4-specific retrieval or fixation sensitivity, so do not assign either as the cause without run-specific evidence. |
| Cytoplasm or cell borders dominate the staining. | That distribution conflicts with BRD4's nuclear and chromosomal localization (UniProt O60885: subcellular location; HPA: ubiquitous nuclear expression). | Compare with the nuclear counterstain and a known-positive section; review antibody and detection controls for nonspecific signal (standard IHC practice). Do not score cytoplasmic or membrane color alone as a positive BRD4 result. |
| Color persists in a no-primary-antibody control. | The primary antibody cannot account for color in that control; endogenous detection activity or reagent background may contribute (standard IHC practice). | Review blocking and, for enzyme-based chromogenic detection, the relevant endogenous-enzyme control or quench (standard IHC practice). Reassess BRD4 only after the control background is addressed. |
| Expected nuclei stain, but diffuse color obscures their edges. | High background may reflect assay conditions rather than a change in BRD4 localization (standard IHC practice; UniProt O60885: nucleus). | Review the IHC-validated antibody's recommended conditions, antibody concentration, blocking, and washes (standard IHC practice). Keep a positive reference in the comparison so reducing background does not hide genuine nuclear signal. |
| Only an unfamiliar cell population stains. | Its identity alone cannot establish cross-reactivity: BRD4 is ubiquitously expressed and HPA reports low tissue specificity (UniProt O60885: tissue specificity; HPA: tissue IHC). | Check whether color is nuclear and whether named High populations stain in the same run (HPA: tissue IHC). If expected nuclei remain clear, investigate cross-reactivity and detection background with appropriate controls (standard IHC practice). |
| Mitotic figures show conspicuous chromosome-associated signal. | BRD4 preferentially localizes to mitotic chromosomes (UniProt O60885: subcellular location), also reported as an additional ICC-IF location (HPA: subcellular). | Assess those figures alongside the broader nuclear pattern and control slide. Do not reject a section solely for mitotic signal; if color extends beyond cellular structures, check background using standard IHC controls (standard IHC practice). |
Experiment evidence
IHC & IF images showing BRD4 staining
M00123 · IHCImmunohistochemical analysis of paraffin-embedded human kidney, using Brd4 Antibody.
M00123 · IFImmunofluorescent analysis of Hela cells, using Brd4 Antibody .
A00123-2 · IFIF analysis of BRD4 using anti-BRD4 antibody (A00123-2). BRD4 was detected in an immunocytochemical section of PC-3 cells. Enzyme antigen re
A00123-3 · IFIF analysis of BRD4 using anti-BRD4 antibody (A00123-3). BRD4 was detected in an immunocytochemical section of MCF-7 cells. Enzyme antigen r
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000141867-BRD4/tissue/cerebral+cortex#imid_18795034
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000141867-BRD4/tissue/colon#imid_18794944
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000141867-BRD4/tissue/liver#imid_18794945
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000141867-BRD4/tissue/kidney#imid_18794946
HPA · ICC-IF U-251MGHuman Protein Atlas immunofluorescence, U-251MG, antibody HPA015055; green = BRD4, blue = nucleus, red = microtubules.
HPA · ICC-IF U-251MGHuman Protein Atlas immunofluorescence, U-251MG, antibody HPA015055; green = BRD4, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for BRD4 IHC & IF
🧪Run bone marrow first: hematopoietic cells should show BRD4 staining (HPA: High in bone marrow hematopoietic cells), with signal assessed in nuclei (UniProt O60885: nuclear localization). HPA detects BRD4 in all 45 scored tissues, so no tissue is a validated negative; use no-primary and isotype controls, and treat any unstained cells on the positive slide as observations rather than established BRD4-negative cells (HPA: no negative rows; detected in all 45 scored tissues).
Positive control tissue: Adipose tissue (Adipocytes, HPA High)
Negative control tissue: None in HPA: BRD4 is detected in all 45 scored tissues. Use a no-primary (secondary-only) and an isotype control instead.
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show BRD4 in U-251MG, U2OS, MCF-7, PC-3, KOLF2.1J, with annotated localisation: Nucleoplasm (enhanced) (HPA subcellular).
Technical controls: Include a no-primary, secondary-only slide, an isotype control matched to the primary antibody’s host species and clonality, and a BRD4 knockout control or validated peptide-block control where available (standard IHC practice). In bone marrow, block endogenous peroxidase before chromogenic detection and check background in the no-primary slide (standard IHC practice: hematopoietic tissue can contain endogenous peroxidase).
⚠️Feasibility: No target-specific fixation window or fixation effect is reported in the supplied evidence, and the selected M00123 paraffin-section kidney caption does not state a fixative (selected SKU caption: fixative unreported). A BRD4-specific dependence on antigen retrieval is unreported; optimize retrieval empirically for paraffin IHC, and do not assume frozen sections or IF are easier from these data (standard IHC practice; supplied evidence: no processing comparison). Bone marrow’s endogenous peroxidase can confound chromogenic staining, while the expected nuclear signal provides a localization check (standard IHC practice; UniProt O60885: nuclear localization).
HPA tissue IHC evidence for BRD4
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Supported — High consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | High | Protein (IHC) | HPA → |
| Adrenal gland | Glandular cells | High | Protein (IHC) | HPA → |
| Appendix | Glandular cells | High | Protein (IHC) | HPA → |
| Bone marrow | Hematopoietic cells | High | Protein (IHC) | HPA → |
| Breast | Adipocytes | High | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| None in HPA: BRD4 is detected in all 45 scored tissues. Use a no-primary (secondary-only) and an isotype control instead. | ||||
Section 3
Advanced BRD4 IHC Tips
Troubleshoot BRD4 chromogenic IHC by checking nuclear localisation, specimen handling and scoring before interpreting differences between samples (UniProt O60885; HPA tissue IHC).
How should I retrieve BRD4 in paraffin sections with weak nuclear staining?
Start with Tris-EDTA at pH 9.0, heated to 95–98 °C for 20 min (page IHC retrieval setting: nuclear antigen rule). Allow slides to cool consistently, then compare nuclear signal in matched sections processed in the same run; BRD4 is expected in nuclei and can associate with mitotic chromosomes (standard IHC practice; UniProt O60885: subcellular location). If staining remains weak, compare a milder retrieval condition only as a fallback while holding antibody and detection conditions constant (standard IHC practice). Excess retrieval can damage morphology, so assess nuclear detail alongside staining intensity before adopting a revised condition (standard IHC practice).
Could fixation explain variable BRD4 staining between paraffin blocks?
BRD4-specific sensitivity to fixative choice or fixation duration is unknown from the supplied evidence (selected M00123 kidney caption: fixative not stated). Record each block’s fixative and time in fixative, and compare sections with similar processing histories before assigning a biological explanation to different nuclear intensities (standard IHC practice). If new material is available, hold fixation conditions constant across the comparison and assess morphology and staining together; a difference after that comparison still needs validation (standard IHC practice). Do not infer fixation tolerance from the paraffin kidney image, the HPA tissue pattern, or BRD4’s nuclear location (selected M00123 kidney caption; HPA tissue IHC; UniProt O60885: subcellular location).
Where should credible BRD4 staining appear in a chromogenic section?
Score BRD4 primarily in nuclei because UniProt places it in the nucleus and on chromosomes, while HPA describes mainly nucleoplasmic staining with additional mitotic chromosome localisation (UniProt O60885: subcellular location; HPA subcellular). Examine intact nuclei at high magnification and note whether a strong chromogenic signal follows nuclear boundaries rather than diffuse cytoplasm or extracellular material (standard IHC practice). BRD4 associates with acetylated chromatin and may leave chromatin after histone deacetylation, so chromatin association alone should not be treated as a fixed staining pattern (UniProt O60885: subcellular location). Compare adjacent cells and section quality before calling an unusual distribution specific (standard IHC practice).
Can an epitope choice change which BRD4 signal I see?
BRD4 has 3 listed isoforms, A, C and B, so determine the catalog antibody’s mapped epitope and documented isoform coverage before interpreting a negative section (UniProt O60885: isoforms; standard IHC practice). Its bromodomains occupy residues 58–164 and 348–457, and its NET domain occupies 600–682; these coordinates help place a disclosed epitope but do not establish antibody recognition (UniProt O60885: domains). The supplied caption does not specify the M00123 epitope, so staining cannot be assigned to one isoform from that image (selected M00123 kidney caption). Compare independently validated epitopes on matched sections if isoform coverage matters, with retrieval and detection held constant (standard IHC practice).
How can IF help assess BRD4 localisation and cell identity?
Use an IF-validated BRD4 antibody and include a validated marker for the expected cell population, such as adipocytes in adipose tissue, when multiplexing (HPA tissue IHC: high in adipocytes; standard IF practice). Select spectrally separated fluorophores and consider a far-red BRD4 channel if tissue autofluorescence compromises shorter wavelengths (standard IF practice). Because BRD4 is nuclear and has no transmembrane segment, optimise permeabilisation to admit antibody to the nuclear epitope while preserving morphology (UniProt O60885: subcellular location and topology; standard IF practice). Check secondary-only controls and nuclear counterstain alignment, then assess fixative compatibility using IF evidence rather than the paraffin kidney caption (standard IF practice; selected M00123 kidney caption: fixative not stated).
What should I adjust when BRD4 chromogenic staining looks diffuse?
First determine whether the diffuse signal crosses nuclear boundaries: BRD4 is primarily nuclear, whereas widespread extracellular deposit is inconsistent with its reported localisation (UniProt O60885: subcellular location; standard IHC practice). Run a no-primary control to assess detection-system background and inspect whether endogenous peroxidase activity persists after the routine peroxidase block (standard chromogenic IHC practice). Optimise blocking, washing and antibody concentration using the antibody’s documented range, without treating a higher concentration as evidence of specificity (standard IHC practice). Compare clean internal nuclear staining with adjacent damaged or folded regions, and keep development time consistent across slides (HPA tissue IHC: ubiquitous nuclear expression; standard IHC practice).
How should I compare BRD4 staining across paraffin samples? ⚠ ANSWER MARKED FOR VERIFICATION
Define the region of interest before scoring and count viable, interpretable nuclei, because BRD4’s expected signal is nuclear (standard IHC practice; HPA tissue IHC: ubiquitous nuclear expression). Report the percentage of positive nuclei and, if intensity matters, an H-score from 0–300 using intensity categories 0–3 (standard IHC scoring practice). Normalise each result to the number of evaluable nuclei in the same tissue compartment, and report the scored area when comparing cellular density per mm² (standard IHC practice). Apply one threshold, imaging setup and scoring rule across the cohort, with an observer blinded to group where feasible (standard IHC practice).
How do I distinguish true BRD4 staining from artefact?
Give greatest weight to reproducible staining in intact nuclei: BRD4 is nuclear, and HPA reports a ubiquitous nuclear pattern with high staining in several listed cell populations (UniProt O60885: subcellular location; HPA tissue IHC). Check the claimed cell population against morphology and a relevant marker when identity is uncertain, rather than assigning a chromogenic nucleus to a cell type by colour alone (standard IHC practice). Treat edge-only signal, necrotic areas and staining outside cells as suspect, and compare them with interior viable tissue (standard IHC practice). A no-primary control and peroxidase block help identify detection background or endogenous enzyme signal before biological interpretation (standard chromogenic IHC practice).
Boster reagents
Best BRD4 / Bromodomain-containing protein 4 IHC Antibodies
Anti-BRD4 antibodies include paraffin-section IHC data from human kidney and IF/ICC data from PC-3 and MCF-7 cells; all three list human, mouse and rat reactivity (catalog images; catalog reactivity).
Real IHC data
Anti-Brd4 Rabbit Monoclonal Antibody
Cat # M00123
Real IF data
Anti-BRD4 Antibody ®
Cat # A00123-2
Real IF data
Anti-BRD4 Antibody ®
Cat # A00123-3
M00123 lists IHC and IF applications and shows IHC in paraffin-embedded human kidney (M00123 application list; M00123 IHC caption). A00123-2 shows IF/ICC in PC-3 cells, while A00123-3 shows IF/ICC in MCF-7 cells (A00123-2 and A00123-3 IF captions; catalog application lists).
Which to pick: Choose M00123 for tissue IHC: it is a rabbit monoclonal with a listed 1:50 IHC dilution and an image of paraffin-embedded human kidney; the caption does not report the fixative (M00123 catalog; M00123 IHC caption). For IF/ICC, A00123-2 has a PC-3 image and a listed 5 μg/ml IF dilution, while A00123-3 has an MCF-7 image and reports 5 μg/ml in its IF caption (A00123-2 catalog and IF caption; A00123-3 IF caption). All three list human, mouse and rat reactivity; the cited images demonstrate the stated samples only (catalog reactivity; catalog image captions).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry O60885 (BRD4_HUMAN, Bromodomain-containing protein 4).
- Human Protein Atlas. BRD4 tissue IHC expression (reliability: Supported).
- Human Protein Atlas. BRD4 subcellular location (ICC-IF): Mainly localized to the nucleoplasm. In addition localized to the mitotic chromosome..
- Human Protein Atlas. BRD4 antibody validation summary (4 antibodies).
- Divergent splicing factor SRSF1 signaling promotes inflammation post-CME: the SRSF1/ENPP3 axis acts via inhibition of BRD4 O-GlcNAcylation to enhance NF-κB activation and accelerate heart failure. Theranostics 2025 — PMC12203807.
- Tumoral BRD4 expression in lymph node-negative breast cancer: association with T-bet+ tumor-infiltrating lymphocytes and disease-free survival. BMC cancer 2018 — PMC6053709.
- Validation of Bromodomain and Extraterminal proteins as therapeutic targets in neurofibromatosis type 2. Neuro-oncology advances 2022 — PMC9278623.
- Bromodomain protein 4 is a novel predictor of survival for gastric carcinoma. Oncotarget 2017 — PMC5458191.
- PubMed PMID:11733348 — UniProt-cited evidence.
- PubMed PMID:15057824 — UniProt-cited evidence.
- PubMed PMID:15489334 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for BRD4 (Bromodomain-containing protein 4). Expected localisation Ubiquitous nuclear staining (HPA tissue IHC). Antigen retrieval: Tris-EDTA pH 9.0 HIER, 95–98 °C, 20 min (rule: nuclear antigen). Validated IHC antibody: M00123 at 1:50 (the product's own IHC validation image is shown). Controls (HPA): positive Adipose tissue (Adipocytes); negative None in HPA (detected in all 45 tissues); use no-primary + isotype controls. IHC workflow; specimen preparation unspecified. Protocol steps: 1. Sample: Paraffin-embedded human kidney tissue; fixative not specified (datasheet M00123); 2. Fixation: Image fixative and duration unreported (datasheet M00123); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat-induced epitope retrieval in Tris-EDTA buffer, pH 9.0 , 20 min at 95–98 °C…; 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% normal serum of the secondary host, 30 min , room temperature (standard); 8. Primary antibody: Rabbit monoclonal (clone DBH-2) anti-BRD4, 1:50 (datasheet M00123); 9. Primary incubation: Overnight at 4 °C (standard). Watch for: Fixation: Keep fixation consistent across sections. (standard IHC practice; not target-specific); Caveat: Broad expression limits tissue-negative controls (HPA tissue IHC); Isoform / epitope: 3 isoforms (A, C, B); verify epitope coverage (UniProt); Regulation: Deacetylation reduces chromatin binding (UniProt). Evidence: UniProt O60885, HPA tissue IHC · Supported, HPA ICC-IF · Mainly localized to the nucleoplasm. In addition localized to the…, Datasheet M00123, PMC12203807, PMC6053709. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/BRD4/immunohistochemistry-ihc-guide.